Please Wait.....
Report
Global Markets for Generic Drugs
Market Research Report I 2024-01-15 I 126 Pages I BCC Research
Description
Report Scope:
The report discusses the current size and growth of the market for generic drugs, both in global terms and broken down by the most important national markets. The report covers small molecule drugs and biosimilars. It includes market drivers and challenges in the generic drug industry. The competitive landscape includes generic drug sales of key competitors and their ranking in the market. It also covers the emerging trends in the generic drugs industry.
By geographical region, the market has been segregated into North America, Europe, Asia-Pacific, and the Rest of the World. The North America region includes countries such as the U.S., Canada and Mexico; Europe includes Germany, U.K., Italy, and Rest of Europe; Asia-Pacific includes China, India, Japan, and Rest of Asia-Pacific. The estimated values used are based on drug manufacturers' total revenues.
Report Includes:
- 37 data tables and 39 additional tables
- An overview of the global markets for generic (pharmaceutical) drugs
- Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Estimate of the market size and revenue forecast of the market for generic drugs, and corresponding market share analysis based on molecule type and geographic region
- Evaluation of the current and future market potential of generic drugs, as well as the major generics, regulatory landscape and patent cliff within the biopharmaceutical industry
- Discussion of the major market drivers, opportunities and challenges, emerging technologies, and regulations
- Data and market value analyses for the U.S., Canada, Mexico, Germany, the U.K., Italy, China, India and Japan
- Overview of the sustainability trends and factors in the market for generic drugs, with emphasis on consumer attitudes, ESG scores, case studies and the ESG practices of leading companies
- Analysis of the pipeline for new generic drugs and their impact on the growth of the overall biopharmaceutical products market
- Patent review and analysis of key patent grants
- An analysis of the industry structure, including company market shares, recent M&A activity, and venture funding
- Analysis of the top market players, their global rankings, recent developments, key financials and segmental revenues, and product portfolios
- Profiles of the leading market players
Executive Summary
Summary:
The global market for generic drugs was valued at $REDACTED billion in 2022. The market is forecast to grow from $REDACTED billion in 2023 at a compound annual growth rate (CAGR) of REDACTED% to reach approximately $REDACTED billion by the end of 2028.
The increasing patent cliffs and exclusivities, favorable regulatory policies, and positive changes in prescription patterns are responsible for market growth.
This report segments the global market by molecule type and region. The market is categorized into small-molecule drugs and biosimilars based on molecule type. The small molecule drugs segment, which held the largest share in 2022, is expected to grow at a REDACTED% CAGR during the forecast period. This segment's large share is attributed to the growing medical needs of chronically ill patients. The biosimilars segment is growing at a higher CAGR, REDACTED%, during the forecast period. The increasing prevalence of cancer and immunological diseases drives the need for low-cost biosimilars.
Some companies in this market include Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Viatris Inc., Sun Pharmaceutical Ltd., and Fresenius Kabi.
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in this Update?
Research Methodology
Information Sources
Regional Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Market Summary
Chapter 3 Market Overview
Introduction
Adequate Market Size
Patent-Expired Therapies
Older Products Still Used
Long-Term Use
Straightforward Production Technology
Drugs Used in Primary Care
Biosimilars
Chapter 4 Market Dynamics
Market Drivers
Increasing Patent Cliffs and Loss of Exclusivities
Favorable Healthcare Policies
Changing Physician Attitudes
Market Challenges
Pricing Pressures and Low Profit Margins
Patent Extension Strategies of Innovator Companies
Chapter 5 Market Breakdown by Molecule Type
Global Market for Generic Drugs
Global Generic Drugs Market, by Molecule Type
Small Molecule Generics
Biosimilars
Chapter 6 Market Breakdown by Region
Introduction
North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Rest of Asia-Pacific
Rest of the World
Chapter 7 Sustainability: An ESG Perspective
Introduction to ESG
Sustainability in the Generic Drugs Industry: An ESG Perspective
Key ESG Issues
Environmental Performance of Key Generic Drug Companies
Social Performance of Key Generic Drug Companies
Governance Performance of Key Generic Drug Companies
Case Study
Concluding Remarks from BCC
Chapter 8 Emerging Trends and Developments
Key Trends in the Market
Collaborations for R&D
Rise of Complex Generics in Immunology and Oncology
Improving Portfolio Efficiency
Focus on Emerging Markets
Chapter 9 Regulatory Landscape
Regulatory Overview
U.S.
Evolving Situation in the U.S.
European Union
Japan
Regulation of Biosimilars
EU Provisions
Authorized Generic Drugs
Chapter 10 Competitive Landscape
Competitive Landscape
M&A Analysis
Chapter 11 Company Profiles
ASPEN PHARMACARE
AUROBINDO PHARMA
CIPLA INC.
DR. REDDY'S LABORATORIES LTD.
FRESENIUS KABI
LUPIN LTD.
SANDOZ
SUN PHARMACEUTICAL INDUSTRIES LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.
List of Tables
Summary Table A : Global Market for Generic Drugs, by Molecule Type, Through 2028
Summary Table B : Global Market for Generic Drugs, by Region, Through 2028
Table 1 : List of Block Buster Drugs Undergoing Patent Expiry in Coming Years
Table 2 : Global Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 3 : Global Market for Generic Drugs, by Top 10 Countries, Through 2028
Table 4 : Global Top Selling Pharmaceuticals, 2022
Table 5 : Global Market for Generic Drugs, by Molecule Type, Through 2028
Table 6 : Global Market for Small Molecule Generics, by Region, Through 2028
Table 7 : Approved Biosimilar Products in the U.S.
Table 8 : Global Market for Biosimilars, by Region, Through 2028
Table 9 : Global Market for Generic Drugs, by Region, Through 2028
Table 10 : North American Market for Generic Drugs, Through 2028
Table 11 : U.S. Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 12 : Canadian Key Therapeutic Areas in Retail and Hospital Purchases, 2022
Table 13 : Canadian Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 14 : European Market for Generic Drugs, by Country, Through 2028
Table 15 : German Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 16 : French Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 17 : Italian Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 18 : U.K. Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 19 : Spanish Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 20 : Penetration of Generic Drugs in the Pharmaceutical Market in Other European Countries, 2022
Table 21 : Rest of the European Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 22 : Asia-Pacific Market for Generic Drugs, by Country, Through 2028
Table 23 : Chinese Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 24 : Japanese Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 25 : Indian Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 26 : Rest of Asia-Pacific Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 27 : RoW Market for Generic Drugs Compared with the Total Pharmaceutical Market, Through 2028
Table 28 : ESG Rankings for Major Generic Drugs Companies, 2023*
Table 29 : ESG: Environmental Overview
Table 30 : ESG: Social Overview
Table 31 : ESG: Governance Overview
Table 32 : Teva: ESG Ratings Received, 2022
Table 33 : Collaborations for R&D and Licensing Agreements, 2022 and 2023
Table 34 : Portfolio Expansion Activities of Key Generic Companies
Table 35 : Requirements for NDA and ANDA Applications
Table 36 : Leading Generic Drug Companies, by Sales, 2022
Table 37 : Comparative Analysis of Top Three Competitors
Table 38 : M&A Analysis of Generic Drugs Markets, 2022 and 2023
Table 39 : Aspen Pharmacare Holdings Ltd.: Company Snapshot
Table 40 : Aspen Pharmacare Holdings Ltd.: Financials, 2021 and 2022
Table 41 : Aspen Pharmacare Holdings Ltd: Key Product Portfolio
Table 42 : Aspen Pharmacare Holdings Ltd.: Recent Developments, 2023
Table 43 : Aurobindo Pharma Ltd.: Company Snapshot
Table 44 : Aurobindo Pharma Ltd.: Financials, 2021 and 2022
Table 45 : Aurobindo Pharma Ltd.: Recent Developments, 2022
Table 46 : Cipla Inc.: Company Snapshot
Table 47 : Cipla Inc.: Financials, 2021 and 2022
Table 48 : Cipla Inc.: Key Product Launches, by Region, 2022
Table 49 : Cipla Inc.: Recent Developments, 2023
Table 50 : Dr. Reddy's Laboratories Ltd.: Company Snapshot
Table 51 : Dr. Reddy's Laboratories Ltd.: Financials, 2021 and 2022
Table 52 : Dr. Reddy's Laboratories Ltd.: Biosimilars Portfolio
Table 53 : Dr. Reddy's Laboratories Ltd.: Recent Developments, 2022-2023
Table 54 : Fresenius Kabi AG: Company Snapshot
Table 55 : Fresenius Kabi AG: Biosimilars Portfolio
Table 56 : Fresenius Kabi AG: Biosimilar Products in Pipeline
Table 57 : Fresenius Kabi AG: Recent Developments, 2022-2023
Table 58 : Lupin Ltd.: Company Snapshot
Table 59 : Lupin Ltd.: Financials, 2021 and 2022
Table 60 : Lupin Ltd.: Recent Developments, 2023
Table 61 : Sandoz Group AG: Company Snapshot
Table 62 : Sandoz Group AG: Financials, 2021 and 2022
Table 63 : Sandoz Group AG: Product Portfolio
Table 64 : Sandoz Group AG: Key Biosimilar Products in Phase III and Registration
Table 65 : Sandoz Group AG: Recent Developments, 2023
Table 66 : Sun Pharmaceutical Industrial Ltd.: Company Snapshot
Table 67 : Sun Pharmaceutical Industrial Ltd.: Financials, 2021 and 2022
Table 68 : Teva Pharmaceutical Industrial Ltd.: Company Snapshot
Table 69 : Teva Pharmaceutical Industrial Ltd.: Financials, 2021 and 2022
Table 70 : Teva Pharmaceutical Industrial Ltd.: Biosimilars Portfolio
Table 71 : Teva Pharmaceutical Industrial Ltd.: Recent Developments, 2023
Table 72 : Viatris Inc.: Company Snapshot
Table 73 : Viatris Inc.: Financials, 2021 and 2022
Table 74 : Viatris Inc.: Recent Developments, 2022-2023
List of Figures
Summary Figure A : Global Market for Generic Drugs, by Molecule Type, 2020-2028
Summary Figure B : Global Market for Generic Drugs, by Region, 2020-2028
Figure 1 : Generic Drugs Market Dynamics
Figure 2 : Generic Drugs Approved in the U.S., 2019-2022
Figure 3 : Regulatory Pathways for Small Molecule Generics and Biosimilars
Figure 4 : Global Market Shares of Generic Drugs, by Molecule Type, 2022
Figure 5 : Global Market for Small Molecule Generics, 2020-2028
Figure 6 : Global Market for Biosimilars, 2020-2028
Figure 7 : Snapshot of Global Market for Generic Drugs, by Region
Figure 8 : Global Market Shares of Generic Drugs, by Region, 2022
Figure 9 : Annual Savings from Biosimilars and Generics in the U.S., 2019-2022
Figure 10 : European Market Shares of Generic Drugs, by Country, 2022
Figure 11 : Asia-Pacific Market Shares of Generic Drugs, by Country, 2022
Figure 12 : ESG Pillars
Figure 13 : Advantages of ESG for Companies in the Generic Drugs Market
Figure 14 : Key Focus Areas in ESG Metrics in the Generics Market
Figure 15 : Teva: ESG Indicators, 2022
Figure 16 : Emerging Trends in the Generic Drugs Market
Figure 17 : Aspen Pharmacare Holdings Ltd.: Financials, 2021 and 2022
Figure 18 : Aspen Pharmacare Holdings Ltd.: Market Share, by Business Segment, 2022
Figure 19 : Aspen Pharmacare Holdings Ltd.: Revenue Share, by Region, 2022
Figure 20 : Aurobindo Pharma Ltd.: Financials, 2021 and 2022
Figure 21 : Aurobindo Pharma Ltd.: Revenue Share, by Business Segment, 2022
Figure 22 : Aurobindo Pharma Ltd.: ANDA Filings, by Region, FY2022
Figure 23 : Cipla Inc.: Financials, 2021 and 2022
Figure 24 : Cipla Inc.: Revenue Share, by Business Segment, 2022
Figure 25 : Cipla Inc.: ANDAs Pipeline, FY 2022
Figure 26 : Dr. Reddy's Laboratories Ltd.: Financials, 2021 and 2022
Figure 27 : Dr. Reddy's Laboratories Ltd.: Revenue Share, by Business Segment, 2022
Figure 28 : Dr. Reddy's Laboratories Ltd.: Global Generics Revenue Share, by Therapeutic Area, 2022
Figure 29 : Dr. Reddy's Laboratories Ltd.: Revenue Share, by Country, 2022
Figure 30 : Lupin Ltd.: Financials, 2021 and 2022
Figure 31 : Lupin Ltd.: Revenue Share, by Business Segment, 2022
Figure 32 : Lupin Ltd.: India Revenue Share, by Therapeutic Area, 2022
Figure 33 : Timeline of Novartis and Sandoz Separation
Figure 34 : Sandoz Group AG: Financials, 2021 and 2022
Figure 35 : Sandoz Group AG: Market Share, by Business Segment, 2022
Figure 36 : Sandoz Group AG: Revenue Share, by Region, 2022
Figure 37 : Sun Pharmaceutical Industrial Ltd.: Financials, 2021 and 2022
Figure 38 : Sun Pharmaceutical Industrial Ltd.: Revenue Share, by Business Segment, 2022
Figure 39 : Cumulative ANDAs Filed and Approved in the U.S., FY 2019-FY 2023
Figure 40 : Teva Pharmaceutical Industrial Ltd.: Financials, 2021 and 2022
Figure 41 : Teva Pharmaceutical Industrial Ltd.: Revenue Share, by Region, 2022
Figure 42 : Viatris Inc.: Financials, 2021 and 2022
Figure 43 : Viatris Inc.: Market Share, by Business Segment, 2022
Figure 44 : Viatris Inc.: Revenue Share, by Region, 2022
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security